National Cancer Institute Experience in Micro-invasive Breast Carcinoma Treatment and Outcome

Mohamed Salama; Amira Khater; Iman Adel; Marwa Selim

doi:10.3889/oamjms.2022.7613

Authors

Mohamed Salama Department of Surgical Oncology
Amira Khater Department of Cancer Epidemiology and Biostatistics
Iman Adel Department of Histopathology, National Cancer Institute, Cairo University, Cairo, Egypt
Marwa Selim Department of Medical Oncology https://orcid.org/0000-0003-4183-6210

DOI:

https://doi.org/10.3889/oamjms.2022.7613

Keywords:

Micro-invasive breast carcinoma, Carcinoma in situ, ductal carcinoma in situ, Breast-conserving surgery

Abstract

Abstract
Background: Significant relationship between breast cancer immunophenotype and risk of recurrence either local and/or distant may help determine which patients might benefit more from axillary staging and whether axillary staging is warranted in all cases or not. Patients with microinvasive carcinoma can present with axillary LN. metastasis, with incidence ranges from 0% to 20% . Thus, sentinel node biopsies are considered for patients with microinvasive carcinoma. The role of axillary staging in MIBC is not well defined, with the rate of axillary L.N. metastases ranging 0–11 %. Current studies focus on the clinical characteristics of MIBC. However, only a few studies have evaluated the survival and treatment, especially adjuvant chemotherapy after surgery, for patients with MIBC.
Methods: This is a retrospective study of 139 cases diagnosed with microinvasive breast carcinoma from 2011 to 2015 who were identified in the National Cancer Institute, Cairo University. The pathologic database of our hospital was searched to identify patients with a pathologic diagnosis of MIBC on surgical specimens. The clinical features, sonographic and mammographic images and pathology records were reviewed.
Results: There is increased incidence of MIBC over the past decade. Patients with MIBC were managed surgically with BCS. MIBC have the good prognosis. However, patients who are negative hormonal receptors have relatively substantial risk of relapse within the first 5 years after surgical operation. Adjuvant chemotherapy can only improve the outcomes of patients with negative hormonal receptors. Further studies with prolonged follow-up of large cohort are warranted to assess the prognostic significance and treatment of this lesion.
Keywords: MIBC, CIS, DCIS, BC

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30. http://doi.org/10.3322/caac.21332 PMid:26742998 DOI: https://doi.org/10.3322/caac.21332

American Cancer Society. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.

Hoda SA, Chiu A, Prasad ML, Giri D, Hoda RS. Are microinvasion and micrometastasis in breast cancer mountains or molehills? Am J Surg. 2000;180(4):305-8. http://doi.org/10.1016/s0002-9610(00)00464-5 PMid:11113441 DOI: https://doi.org/10.1016/S0002-9610(00)00464-5

Ko BS, Lim WS, Kim HJ, Yu JH, Lee JW, Kwan SB, et al. Risk factor for axillary lymph node metastases in microinvasive breast cancer. Ann Surg Oncol. 2012;19(1):212-6. http://doi.org/10.1245/s10434-011-1812-2 PMid:21633867 DOI: https://doi.org/10.1245/s10434-011-1812-2

Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004;96(12):906-20. http://doi.org/10.1093/jnci/djh164 PMid:15199110 DOI: https://doi.org/10.1093/jnci/djh164

Adamovich TL, Simmons RM. Ductal carcinoma in situ with microinvasion. Am J Surg. 2003;186(2):112-6. http://doi.org/10.1016/s0002-9610(03)00166-1 PMid:12885600 DOI: https://doi.org/10.1016/S0002-9610(03)00166-1

Guth AA, Mercado C, Roses DF, Darvishian F, Singh B, Cangiarella JF. Microinvasive breast cancer and the role of sentinel node biopsy: An institutional experience and review of the literature. Breast J. 2008;14(4):335-9. http://doi.org/10.1111/j.1524-4741.2008.00594.x PMid:18537917 DOI: https://doi.org/10.1111/j.1524-4741.2008.00594.x

Intra M, Zurrida S, Maffini F, Sonzogni A, Trifirò G, Gennari R, et al. Sentinel lymph node metastasis in microinvasive breast cancer. Ann Surg Oncol. 2003;10(10):1160-5. http://doi.org/10.1245/aso.2003.04.009 PMid:14654471 DOI: https://doi.org/10.1245/ASO.2003.04.009

Zhang W, Gao EL, Zhou YL, Zhai Q, Zou ZY, Guo GL, et al. Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer. World J Surg Oncol. 2012;10:262. http://doi.org/10.1186/1477-7819-10-262 PMid:23216911

Yu KD, Wu LM, Liu GY, Wu J, Di GH, Shen ZZ, et al. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. Ann Surg Oncol. 2011;18:1342-8. http://doi.org/10.1245/s10434-010-1407-3 PMid:21042943 DOI: https://doi.org/10.1245/s10434-010-1407-3

Perry N, Broeders M, de Wolf C. European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis. 4th ed. Luxembourg: Office for Official Publications of the European Communities; 2006.

Bianchi S, Vezzosi V. Microinvasive carcinoma of the breast. Pathol Oncol Res. 2008;14(2):105-11. http://doi.org/10.1007/s12253-008-9054-8 PMid:18493870 DOI: https://doi.org/10.1007/s12253-008-9054-8

de Mascarel I, MacGrogan G, Mathoulin-Pélissier S, Soubeyran I, Picot V, Coindre JM. Breast ductal carcinoma in situ with microinvasion: A definition supported by a long-term study of 1,248 serially sectioned ductal carcinomas. Cancer. 2002;94(8):2134-42. http://doi.org/10.1002/cncr.10451 PMid:12001109 DOI: https://doi.org/10.1002/cncr.10451

Solin LJ, Fowble BL, Yeh IT, Kowalyshyn MJ, Schultz DJ, Weiss MC, et al. Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys. 1992;23(5):961-8. http://doi.org/10.1016/0360-3016(92)90900-3 PMid:1322388 DOI: https://doi.org/10.1016/0360-3016(92)90900-3

Shatat L, Gloyeske N, Madan R, O’Neil M, Tawfik O, Fan F. Microinvasive breast carcinoma carries an excellent prognosis regardless of the tumor characteristics. Hum Pathol. 2013;44(12):2684-9. http://doi.org/10.1016/j.humpath.2013.07.010 PMid:24071019 DOI: https://doi.org/10.1016/j.humpath.2013.07.010

Wang L, Zhang W, Lyu S, Liu X, Zhang T, Liu S, et al. Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast. Tumour Biol. 2015;36(4):2241-8. http://doi.org/10.1007/s13277-014-2652-z PMid:25801239 DOI: https://doi.org/10.1007/s13277-014-2652-z

Sopik V, Sun P, Narod SA. Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ. Breast Cancer Res Treat. 2018;167(3):787-95. http://doi.org/10.1007/s10549-017-4572-2 PMid:29119353 DOI: https://doi.org/10.1007/s10549-017-4572-2

Margalit DN, Sreedhara M, Chen YH, Catalano PJ, Nguyen PL, Golshan M, et al. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy. Ann Surg Oncol. 2013;20(3):811-8. http://doi.org/10.1245/s10434-012-2640-8 PMid:22956068 DOI: https://doi.org/10.1245/s10434-012-2640-8

Vieira CC, Mercado CL, Cangiarella JF, Moy L, Toth HK, Guth AA. Microinvasive ductal carcinoma in situ: Clinical presentation, imaging features, pathologic findings, and outcome. Eur J Radiol. 2010;73(1):102-7. http://doi.org/10.1016/j.ejrad.2008.09.037 PMid:19026501 DOI: https://doi.org/10.1016/j.ejrad.2008.09.037

Ozkan-Gurdal S, Cabioglu N, Ozcinar B, Muslumanoglu M, Ozmen V, Kecer M, et al. Factors predicting microinvasion in Ductal carcinoma in situ. Asian Pac J Cancer Prev 2014;15(1):55-60. http://doi.org/10.7314/apjcp.2014.15.1.55 PMid:24528005 DOI: https://doi.org/10.7314/APJCP.2014.15.1.55

Yao JJ, Zhan WW, Chen M, Zhang XX, Zhu Y, Fei XC, et al. Sonographic features of ductal carcinoma in situ of the breast with microinvasion: Correlation with clinicopathologic findings and biomarkers. J Ultrasound Med. 2015;34(10):1761-8. http://doi.org/10.7863/ultra.15.14.07059 PMid:26324758 DOI: https://doi.org/10.7863/ultra.15.14.07059

Zhang W, Gao EL, Zhou YL, Zhai Q, Zou ZY, Guo GL, et al. Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer. World J Surg Oncol. 2012;10:262. https://doi.org/10.1186/1477-7819-10-262 PMid:23216911 DOI: https://doi.org/10.1186/1477-7819-10-262

Sue GR, Lannin DR, Killelea B, Chagpar AB. Predictors of microinvasion and its prognostic role in ductal carcinoma in situ. Am J Surg. 2013;206(4):478-81. http://doi.org/10.1016/j.amjsurg.2013.01.039 PMid:23791403 DOI: https://doi.org/10.1016/j.amjsurg.2013.01.039

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-82. http://doi.org/10.1126/science.3798106 PMid:3798106 DOI: https://doi.org/10.1126/science.3798106

Rouanet P, Roger P, Rousseau E, Thibault S, Romieu G, Mathieu A, et al. HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: Results from a French regional cohort. Cancer Med. 2014;3(1):134-42. http://doi.org/10.1002/cam4.167 PMid:24407937 DOI: https://doi.org/10.1002/cam4.167

Kuhar CG, Matos E. Human epidermal growth factor receptor 2-positive microinvasive breast carcinoma with a highly aggressive course: A case report. BMC Res Notes. 2014;7:325. http://doi.org/10.1186/1756-0500-7-325 PMid:24884941 DOI: https://doi.org/10.1186/1756-0500-7-325

Wang W, Zhu W, Du F, Luo Y, Xu B. The demographic features, clinicopathological characteristics and cancer-specific outcomes for patients with microinvasive breast cancer: A SEER database analysis. Sci Rep. 2017;7:42045. http://doi.org/10.1038/srep42045 PMid:28165014 DOI: https://doi.org/10.1038/srep42045

Crowe JP, Patrick RJ, Rybicki LA, Escobar PF, Weng D, Budd GT, et al. A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution. Breast. 2006;15(6):728-35. http://doi.org/10.1016/j.breast.2006.03.005 PMid:16716590 DOI: https://doi.org/10.1016/j.breast.2006.03.005

Roses RE, Paulson EC, Sharma A, Schueller JE, Nisenbaum H, Weinstein S, et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2009;18(5):1386-9. http://doi.org/10.1158/1055-9965.EPI-08-1101 PMid:19383888 DOI: https://doi.org/10.1158/1055-9965.EPI-08-1101

Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC Jr., et al. HER2 signaling modulates the equilibrium between pro and antiangiogenic factors via distinct pathways: Implications for HER2-targeted antibody therapy. Oncogene. 2006;25(52):6986-96. http://doi.org/10.1038/sj.onc.1209685 PMid:16715132 DOI: https://doi.org/10.1038/sj.onc.1209685

Kapoor NS, Shamonki J, Sim MS, Chung CT, Giuliano AE, et al. Impact of multifocality and lymph node metastasis on the prognosis and management of microinvasive breast cancer. Ann Surg Oncol. 2013;20(8):2576-81. http://doi.org/10.1245/s10434-013-2924-7 PMid:23468047 DOI: https://doi.org/10.1245/s10434-013-2924-7

Gentilini O, Botteri E, Rotmensz N, Da Lima L, Caliskan M, Garcia-Etienne CA, et al. Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Res Treat. 2009;113(3):577-83. http://doi.org/10.1007/s10549-008-9959-7 PMid:18330695 DOI: https://doi.org/10.1007/s10549-008-9959-7

Gojon H, Fawunmi D, Valachis A. Sentinel lymph node biopsy in patients with microinvasive breast cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2014;40(1):5-11. http://doi.org/10.1016/j.ejso.2013.10.020 PMid:24238761 DOI: https://doi.org/10.1016/j.ejso.2013.10.020

Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with microinvasion. Cancer. 1998;82(12):2382-90. http://doi.org/10.1002/(sici)1097-0142(19980615)82:12<2382:aid-cncr12>3.0.co;2-l PMid:9635531 DOI: https://doi.org/10.1002/(SICI)1097-0142(19980615)82:12<2382::AID-CNCR12>3.0.CO;2-L

Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American society of clinical oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23(30):7703-20. http://doi.org/10.1200/JCO.2005.08.001 PMid:16157938 DOI: https://doi.org/10.1200/JCO.2005.08.001

Wilkie C, White L, Dupont E, Cantor A, Cox CE. An update of sentinel lymph node mapping in patients with ductal carcinoma in situ. Am J Surg. 2005;190(4):563–6. http://doi.org/10.1016/j.amjsurg.2005.06.011 PMid:16164920 DOI: https://doi.org/10.1016/j.amjsurg.2005.06.011

Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast conserving surgery. Cancer. 1985;56(5):979-90. http://doi.org/10.1002/1097-0142(19850901)56:5<979:aid-cncr2820560502>3.0.co;2-n PMid:2990668 DOI: https://doi.org/10.1002/1097-0142(19850901)56:5<979::AID-CNCR2820560502>3.0.CO;2-N

Morrow M, Harris JR, Schnitt SJ. Surgical margins in lumpectomy for breast cancer, bigger is not better. N Engl J Med. 2012;367(1):79-82. http://doi.org/10.1056/NEJMsb1202521 PMid:22762325 DOI: https://doi.org/10.1056/NEJMsb1202521

Lynch SP, Lei X, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang H, et al. Breast cancer multifocality and multicentricity and locoregional recurrence. Oncologist. 2013;18(11):1167-73. http://doi.org/10.1634/theoncologist.2013-0167 PMid:24136008 DOI: https://doi.org/10.1634/theoncologist.2013-0167

Abdel Hadi M. Mastectomy Versus Breast Conserving Surgery: A Single Surgeon’s Audit from a Developing Country. Breast Surgery Division, King Fahd Hospital of the University, Al Khobar Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia; 2019.

Neri A, Marrelli D, Megha T, Bettarini F, Tacchini D, De Franco L, et al. Clinical significance of multifocal and multicentric breast cancers and choice of surgical treatment: A retrospective study on a series of 1158 cases. BMC Surg. 2015;15(1):1. http://doi.org/10.1186/1471-2482-15-1 PMid:25586679 DOI: https://doi.org/10.1186/1471-2482-15-1

Bertozzi N, Pesce M, Santi PL, Raposio E. Oncoplastic breast surgery: Comprehensive review. Eur Rev Med Pharmacol Sci. 2017;21:2572-85. PMid:28678328 DOI: https://doi.org/10.1016/j.amsu.2017.07.048

Benda RK, Yasuda G, Sethi A, Gabram SG, Hinerman RW, Mendenhall NP. Breast boost: Are we missing the target? Cancer. 2003;97(4):905-9. http://doi.org/10.1002/cncr.11142 PMid:12569589 DOI: https://doi.org/10.1002/cncr.11142

Esposito A, Criscitiello C, Salè EO, Curigliano G. Optimal adjuvant chemotherapy in breast cancer: Selection of agents. Expert Rev Clin Pharmacol. 2014;7(5):605-11. http://doi.org/10.1586/17512433.2014.945429 PMid:25080998 DOI: https://doi.org/10.1586/17512433.2014.945429

Telli ML, Sledge GW. The future of breast cancer systemic therapy: The next 10 years. J Mol Med (Berl). 2015;93(2):119-25. http://doi.org/10.1007/s00109-014-1238-y PMid:25566982 DOI: https://doi.org/10.1007/s00109-014-1238-y

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.